“…[12] A large number of molecules bearing the pyranm oiety display aw ide-ranging spectrum of pharmacological activities in conditions such as asthma, hypertension, urinary diseases, andi schemia, and currently,many are in use in the treatment of variety of diseases. [22][23][24][25][26] Thus, the synthesis of substituted pyran derivatives has been the topic of many research investigations, and severala pproaches have been pursued using variousc atalysts, including hexamethylenetetramine-bromine (HMTAB), [27] H 6 P 2 W 12 O 62 .H 2 O, [28] rare-earth perfluorooctanoate (RE(PFO) 3 ) , [29] phenylboronic acid, [30] silica-gel-supported polyphosphoric acid (PPA-SiO 2 ), [31] per-6-amino-b-cyclodextrin, [32] l-proline, [33] 4-dimethylaminopyridine( DMAP), [34] 1-butyl-3-methylimidazolium tetrafluoroborate (Bmim[BF 4 ]), [35] MNP@P [imEt][Br], [36] tetra-n-butylammonium fluoride (TBAF) [37] amongst others. However, many of these procedures have one or more drawbacks such as moderate yields, requirement of expensive reagents, toxic organic solvents, stoichiometric catalysts, extreme reaction conditions, lengthy procedures,o rl ong reactiont imes,.…”